MedTrace Logo

Ivermectin for Severe COVID-19 Management

NCT04646109 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2021-01-27

Study results available
· View outcomes & findings →

Summary

In this multicenter study; it was aimed to investigate the effectiveness and safety of ivermectin use in the treatment of patients with severe COVID-19 pneumonia that have no mutations which alter ivermectin metabolism and cause side effects.

Conditions

Interventions

DRUG

Ivermectin

Ivermectin 5mg/5ml solution was manufactured by NEUTEC™ Pharmaceutical Company-Turkey, under "Good Manufacturing Practices" (GMP) certification conditions.

Sponsors & Collaborators

  • NeuTec Pharma

    collaborator INDUSTRY

  • Afyonkarahisar Health Sciences University

    lead OTHER

Principal Investigators

  • Nurullah Okumuş, Prof. Dr. · Afyonkarahisar Health Science University, Afyonkarahisar, Turkey

  • Neşe Demirtürk, A. Prof. Dr. · Afyonkarahisar Health Science University, Afyonkarahisar, Turkey

  • Rıza A. Çetinkaya, Prof. Dr. · Haydarpasa Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey

  • Rahmet Güner, Prof. Dr. · Yıldırım Beyazıt University, Ankara City Hospital, Ankara, Turkey

  • İsmail Y. Avcı · Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Turkey

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-11
Primary Completion
2020-09-02
Completion
2020-09-02

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04646109 on ClinicalTrials.gov